Source: Adhy Savala / Unsplash. License: Unsplash License.
Quick Answer: Pediatrix Medical Group, the Sunrise-based physician services company that trades on the NYSE as MD, reported third-quarter 2026 net revenue of $501.4 million, up 1.7% from a year earlier, with adjusted EBITDA of $85.5 million and adjusted earnings per share of $0.72. GAAP net income fell to $47.0 million from $71.7 million because the 2025 quarter included a $20.9 million gain on divested businesses. Management narrowed its full-year 2026 adjusted EBITDA outlook to $290 million to $300 million.
What did Pediatrix report for the third quarter of 2026?
Pediatrix released its results for the three months ended September 30, 2026, on October 29, 2026, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission the same day. The headline numbers describe a company that is growing slowly on the top line while squeezing more out of each dollar of revenue and each share of stock.
Net revenue reached $501.4 million, compared with $492.9 million in the third quarter of 2025, an increase of $8.5 million. Income from operations was $65.2 million, down from $68.1 million. Net income was $47.0 million, or $0.59 per diluted share, compared with $71.7 million, or $0.84 per diluted share, a year earlier. On an adjusted basis, which excludes items such as transformational and restructuring costs and the prior-year divestiture gain, earnings rose to $0.72 per share from $0.67.
Adjusted EBITDA, the measure management uses to frame its annual outlook, was $85.5 million, slightly below the $87.3 million reported in the third quarter of 2025. Chief Executive Officer Mark S. Ordan said in the release that results were “driven by both volume and pricing performing ahead of our expectations.”
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net revenue | $501.4 million | $492.9 million |
| Income from operations | $65.2 million | $68.1 million |
| Net income | $47.0 million | $71.7 million |
| Diluted EPS (GAAP) | $0.59 | $0.84 |
| Adjusted EPS | $0.72 | $0.67 |
| Adjusted EBITDA | $85.5 million | $87.3 million |
| Weighted diluted shares | 79.7 million | 85.6 million |
Why did net income fall while adjusted earnings rose?
The gap between GAAP and adjusted results comes mostly from one item. In the third quarter of 2025, Pediatrix recorded a $20.9 million net gain on investments in divested businesses. No similar gain appeared in 2026. On the earnings call, management noted that other nonoperating items swung to a $0.2 million expense from $19.7 million of income a year earlier, largely because of that comparison.
Without the one-time gain, the underlying business performed modestly better. Adjusted earnings per share rose about 7.5%, helped by a sharply lower share count. Weighted average diluted shares fell to 79.7 million from 85.6 million, a reduction of roughly 6.9%, after an aggressive buyback program. Interest expense also eased to $8.1 million from $8.9 million on modestly lower rates and borrowings.
How did same-unit volumes and pricing perform?
Same-unit revenue, which strips out the effect of acquisitions and practice dispositions, grew 0.6% in the quarter. Chief Financial Officer Kasandra Rossi described the gain on the call as split evenly between pricing and volume: net reimbursement-related factors rose 0.3% and patient volume rose 0.3%. Non-same-unit revenue added another 1.1%, driven by recent acquisitions and partially offset by practice dispositions.
That is a meaningful change from the second quarter. In the three months ended June 30, 2026, same-unit revenue grew 1.9%, but the mix was very different: reimbursement-related factors rose 4.0% while patient volume fell 2.1%. In the third quarter, volume turned positive while pricing growth slowed.
| Same-unit driver | Q3 2026 | Q2 2026 |
|---|---|---|
| Net reimbursement-related | +0.3% | +4.0% |
| Patient volume | +0.3% | (2.1)% |
| Total same-unit revenue | +0.6% | +1.9% |
| Non-same-unit revenue | +1.1% | +2.1% |
Which service lines drove volume?
The earnings release breaks volume into hospital-based and office-based services. Hospital-based patient services, which include neonatal intensive care, fell 0.3% in the third quarter, while office-based patient services grew 2.9%. Neonatal intensive care unit days, the company’s signature volume metric, slipped just 0.1%, which management described on the call as stable.
For the first nine months of 2026, the picture is softer. Hospital-based services were down 1.2%, office-based services were down 0.6% and NICU days were down 1.1%. On the call, management said growth in maternal-fetal medicine was partly offset by lower newborn nursery activity.
| Same-unit volume statistic | Q3 2026 | Nine months 2026 |
|---|---|---|
| Hospital-based patient services | (0.3)% | (1.2)% |
| Office-based patient services | +2.9% | (0.6)% |
| NICU days | (0.1)% | (1.1)% |
Why did pricing growth slow so sharply?
The main reason is a tough comparison. In earlier quarters, Pediatrix benefited from improved cash collections as its revenue cycle management operations stabilized. In the third quarter, the company began lapping those gains. Management said on the call that the comparison created a pricing headwind of a little over 100 basis points. The earnings release similarly cited a strong prior-year cash collections benefit as the offset to otherwise positive reimbursement trends.
Underneath that headwind, three factors pushed pricing up. According to the call, improved payor mix accounted for about 40% of the positive pricing contribution, hospital administrative fees accounted for about 25%, and higher patient acuity, mainly in neonatology, accounted for about 15%. Management described rising acuity as a three-year upward trend. Days sales outstanding, a gauge of how quickly the company collects, were 42.5 days, flat sequentially and down just over half a day from a year earlier.
What is happening with Pediatrix’s payor mix?
Payor mix matters a great deal for a company whose patients are heavily mothers and newborns, a population in which Medicaid plays a large role. The earnings release said the share of services reimbursed by commercial and other non-government payors rose 70 basis points from a year earlier. Management said on the call that the mix was stable compared with the second quarter.
The 10-Q gives approximate shares of net patient service revenue by payor class. Contracted managed care held at about 72% in both periods. Government payors slipped to about 22% from 23%, while private-pay rose to about 2% from 1%.
| Payor class (share of net patient service revenue) | Q3 2026 | Q3 2025 |
|---|---|---|
| Contracted managed care | 72% | 72% |
| Government | 22% | 23% |
| Other third parties | 4% | 4% |
| Private-pay | 2% | 1% |
Are federal policy changes affecting the business?
Analysts pressed management on several policy risks. On changes to Affordable Care Act subsidies, Ordan said the company has “still seen no clear negative effect to date.” On the No Surprises Act independent dispute resolution process, management said out-of-network business is typically under 5% of the total and that it does not expect the review of those rules to be a headwind. Obstetric coding changes are scheduled for 2027, but management declined to predict their direction until final rules are published and said that business is not material.
How did margins and costs move?
Adjusted EBITDA margin for the quarter was about 17.1%, based on $85.5 million of adjusted EBITDA on $501.4 million of revenue, compared with about 17.7% a year earlier. The slight compression reflects cost growth that outpaced the 1.7% revenue increase.
Practice salaries and benefits, by far the largest expense line, rose to $341.5 million from $332.3 million. Management said on the call that clinical salary inflation has run about 3% to 3.5% over the past couple of years, well below the mid-to-high single-digit increases seen at times in the past, and that benefits expense was lower year over year. General and administrative expense rose to $62.7 million from $60.8 million, mainly because of higher incentive compensation tied to stronger results, partly offset by lower software-as-a-service technology costs.
Over nine months, the margin trend is more favorable. Adjusted EBITDA reached $220.1 million on $1,465.4 million of revenue, a margin of about 15.0%, compared with $209.7 million on $1,420.1 million, or about 14.8%, in the first nine months of 2025. Nine-month revenue rose about 3.2% and adjusted EBITDA rose about 5.0%. Adjusted EPS for the nine months climbed to $1.78 from $1.54.
What is Pediatrix’s 2026 guidance?
Pediatrix now expects 2026 adjusted EBITDA of $290 million to $300 million. When it reported second-quarter results on August 4, 2026, the company reaffirmed a range of $280 million to $300 million. The new outlook therefore raises the low end by $10 million while holding the top end, with nine-month adjusted EBITDA running about 5% ahead of the same period in 2025.
Because the company has already produced $220.1 million of adjusted EBITDA through September, the range implies roughly $70 million to $80 million in the fourth quarter. Rossi said on the call that there was “nothing else baked in there” beyond flexibility around volumes and pricing. The company’s reconciliation implies 2026 net income of $153.5 million to $160.8 million, along with about $22.5 million of transformational and restructuring expense. Management declined to discuss 2027, saying budgeting was under way.
What did the portfolio restructuring change?
The current results rest on a reshaping that began in 2024. When Pediatrix reported second-quarter 2024 results in August of that year, it had sold its primary and urgent care clinics and planned to exit all pediatric subspecialty office-based practices by year’s end, while keeping maternal-fetal medicine practices. Healthcare Innovation reported that the exited businesses generated about $200 million of revenue in 2023, and that the subspecialty practices had about 700 physicians at the end of that year. The stated goal was a portfolio in which hospital-based services produce about 80% of revenue, with the divestitures expected to add about $30 million a year to adjusted EBITDA once complete.
Is the restructuring finished?
The major exits appear largely complete, but costs continue. Transformational and restructuring expense was $6.1 million in the third quarter and $19.5 million for nine months, compared with $16.4 million in the first nine months of 2025. The earnings release tied those costs to position eliminations and revenue cycle management transition activities.
The company has shifted back toward selective growth. The 10-Q shows one 2026 acquisition, a maternal-fetal medicine practice bought for total consideration of $7.9 million. On the call, Ordan said the company is considering larger acquisitions adjacent to its women’s and children’s operations, expanding telehealth and assessing selected OB hospitalist opportunities.
How strong is the balance sheet?
Pediatrix ended September with $311.9 million in cash and equivalents, down from $375.2 million at the end of 2025, plus $113.9 million in short-term investments. Total debt was $578 million, consisting of $400 million of 5.375% senior notes due 2030 and $178 million outstanding on its Term A loan. Its $450 million revolving credit line was undrawn. Management put net debt at just over $266 million, or leverage just under 1 times adjusted EBITDA at the guidance midpoint.
How much stock has Pediatrix bought back?
Share repurchases have been the main use of cash. The company spent $83.0 million on buybacks in the third quarter, buying more than 3 million shares, after spending $42.7 million in the second quarter. Management said on the call that it has bought about 10 million shares since August 2025 at an average price of about $23, cutting shares outstanding to 78 million from 87 million at the end of the second quarter of 2025.
According to the 10-Q, the company bought 5.9 million shares for $144.7 million in the first nine months of 2026 under a $250 million program authorized in August 2025, leaving $21.5 million available as of September 30. No new authorization amount was disclosed. Management said future buybacks would be opportunistic.
What does Pediatrix mean for Broward County?
Pediatrix, formerly known as Mednax, is headquartered in Sunrise, and its earnings releases carry a Fort Lauderdale dateline. Its company profile describes about 4,300 affiliated physicians and other clinicians and about 6,500 employees, and its 10-Q says its network provides clinical care in 37 states. That makes it one of a small group of Broward-based companies whose operations reach far beyond South Florida while their corporate functions remain in the county.
| Company snapshot | Detail |
|---|---|
| Ticker | NYSE: MD |
| Headquarters | Sunrise, Broward County |
| Chief executive | Mark S. Ordan |
| Chief financial officer | Kasandra H. Rossi |
| Clinicians | About 4,300 affiliated physicians and other clinicians |
| Footprint | Clinical care in 37 states |
| Nine-month 2026 revenue | $1.47 billion |
| 2026 adjusted EBITDA outlook | $290 million to $300 million |
For the local economy, the results point to a headquarters company in a steadier position than it was two years ago. The 2024 portfolio exits and revenue cycle problems produced heavy losses and restructuring charges. In 2026, the company is profitable on a GAAP basis, carries low leverage and is returning cash to shareholders. At the same time, restructuring expense tied to position eliminations shows that efficiency work is ongoing, and its effect on Broward-based staff is not broken out in the filings.
Frequently Asked Questions
How much revenue did Pediatrix report in Q3 2026?
Pediatrix reported net revenue of $501.4 million for the quarter ended September 30, 2026, up 1.7% from $492.9 million a year earlier.
Why did Pediatrix’s net income decline?
Net income fell to $47.0 million from $71.7 million mainly because the third quarter of 2025 included a $20.9 million net gain on divested businesses. Adjusted EPS rose to $0.72 from $0.67.
What is Pediatrix’s 2026 adjusted EBITDA guidance?
The company expects $290 million to $300 million, narrowed from the $280 million to $300 million range it reaffirmed in August 2026.
Where is Pediatrix Medical Group headquartered?
Pediatrix is headquartered in Sunrise, in Broward County, Florida. The company was formerly known as Mednax and trades on the New York Stock Exchange under the ticker MD.
How much stock is Pediatrix buying back?
Pediatrix spent $83.0 million on buybacks in the third quarter and had $21.5 million left under its $250 million authorization at September 30, 2026.
Sources and Further Reading
- Pediatrix Medical Group Reports Third Quarter Results, Exhibit 99.1 to Form 8-K, Pediatrix Medical Group via U.S. Securities and Exchange Commission
- Form 10-Q for the quarter ended September 30, 2026, Pediatrix Medical Group (Mednax, Inc.) via U.S. Securities and Exchange Commission
- Pediatrix Medical Group (MD) Q3 2026 Earnings Call Transcript, TradingKey
- Pediatrix Medical Group Reports Second Quarter Results, Business Wire
- Pediatrix “Fully Underway” With Sales of Most Office-Based Practices, Healthcare Innovation